Cleveland Clinic's Clinical Research Unit Awarded Clinic's Highest Honor

The CTSC is pleased to recognize the achievement of Cleveland Clinic's CTSC-funded Clinical Research Unit. The Clinical Research Unit team received Cleveland Clinic's highest honor in an annual award ceremony, accepting a Caregiver Award in the category of Teamwork. Chosen after an extensive selection process, the team's members represent the "best of the best" among Cleveland Clinic for outstanding contributions and initiatives representing Cleveland Clinic's mission, vision and values.

Under the leadership of Serpil Erzurum, MD, Wilson Tang, MD, and Lara Jehi, MD, this dedicated group of physicians, nurses, lab technicians, administrators, informaticists, and research coordinators, managed and executed nearly 200 clinical research projects in the past year. They conducted 4,000 research patient visits, covering 35 medical specialties, while collecting and processing 20,000 human lab samples. Accomplishing this required meticulous and extensive monitoring of complex research protocols, targeted weekend interventions, and dispatching team members to study locations that met the needs of participants. The Award honors the team's hard work, collaboration, and commitment.

The Clinical Research Unit is a centralized facility designed to provide an optimal clinical research setting. The Unit, one of three funded within the Clinical & Translational Science Collaborative (CTSC), is a joint venture of Cleveland Clinic, University Hospitals Case Medical Center, and MetroHealth. The Unit's mission is to provide a high-quality research setting that facilitates clinical research and accelerates the translation of discoveries into clinical practice.

Researchers: Register for an ORCID ID

NIH has now adopted the ORCID ID, a free, open-source unique identifying number. Learn more about ORCID.

It is also recommended that researchers link their ORCID ID to their CV in NIH's SciENcv, which creates a current, customizable biobit on NIH grant form pages for any NIH grant.

If you would like to learn more about how to register and link your ORCID number, please contact Clara Pelfrey, Evaluation Director.
research setting. The Unit, one of three funded within the Clinical & Translational Science Collaborative, provides inpatient and outpatient settings for investigators and their research participants, ensuring a caring clinical research environment and proper adherence to protocols. For more information on utilizing the Clinical Research Units visit their website.

Please join us in congratulating the Cleveland Clinic Clinical Research Unit on this outstanding achievement.

**News**

**Cleveland’s Women of Note 2014: Dr. Pamela Davis**

Our own PI and Dean of CWRU’s Medical School has been named among Crain’s Cleveland Business's 2014 Women of Note

When Dr. Pamela B. Davis was 14 years old, her grandmother died after a brutal battle with breast cancer. It was a seminal moment in Davis’ life - one that would set her on a path to become a highly regarded medical researcher and the top administrator at one of the nation’s leading medical schools.

"I knew I was smart enough and scientific enough and capable enough to go out there and make sure no one died like that again," Davis said.

Today, the bulk of Davis’ time is spent meeting with donors, faculty and students in her capacity as dean of Case Western Reserve University’s School of Medicine, though she still manages to see a handful of patients. Doing so keeps her grounded, she said, and reminds her why she entered the profession in the first place.

"Your health is one of the most fundamental human rights - a fundamental human value," Davis said. "Everyone should have access to good health, and this is an opportunity to change the world in a positive way. There are few professions that allow you that opportunity."

Read the full article at Crain’s Cleveland.

**Congratulations to the June 2014 CTSC Core Utilization Pilot Award Recipient**

Brian Cobb, PhD
Case Western Reserve University School of Medicine  "Liver-Mediated Immune Regulation"

Please join us in congratulating Dr. Cobb’s success!

**Research Highlights**

**Spotlight On: The Development Disabilities Practice-Based Research Network (PBRN)**

A new kind of PBRN, facilitating the evolution of primary care for all patients

Practice-Based Research Networks (PBRNs) are organizations of community healthcare practices that collaborate with academic and community partners to improve health care through translational research, particularly primary care delivered in community practices. PBRNs were developed to assure that research leads to better health outcomes because it is informed by front-line community based clinicians. In PBRNs, clinicians are involved in the entire research process, including determining the research agenda, framing and defining the research questions, informing the design of the study, participating in data collection, interpreting study results, disseminating study findings, and incorporating new knowledge into clinical practice.

The federal government regards persons with developmental disabilities (DD) to be a “priority population” for research, and many governmental agencies include them in their lists of “medically underserved populations.” Developmental disabilities include a wide variety of chronic conditions that cause significant lifelong physical or mental impairments. Examples include intellectual disabilities of any cause, cerebral palsy, autism spectrum disorder, and Down syndrome.

For the past 20 years, Dr. Carl Tyler MD, MSc, a practicing physician at the Cleveland Clinic, has focused his work on improving the health and health care of persons with DD through clinical care, research, education, and training. After completing a 3-year NIH-sponsored fellowship in Practice-Based Research Design and Methodology at CWRU under mentors and PBRN Shared Resource Directors James Werner PhD MSSA and Kurt Stange MD PhD, Dr. Tyler received additional funding to create a Development Disabilities Learning Collaborative.
Tyler received additional funding to create a Development Disabilities Learning Collaborative with local stakeholders. The success of the DD Learning Collaborative led to the creation of the Developmental Disabilities (DD) PBRN. The network is devoted to conducting translational research with developmentally disabled patients and their health and service providers.

The DD PBRN is the only PBRN in the country dedicated to conducting translational research with DD patients and their health and service providers. In addition to receiving infrastructure support from the PBRN Shared Resource, this new PBRN is supported by high levels of stakeholder investment including the Arc of Greater Cleveland, United Cerebral Palsy of Greater Cleveland, clinicians from local hospital systems, residential care providers, as well as patients with developmental disabilities and their family advocates. This diverse group has excellent research potential and recently submitted a proposal to the Patient Centered Outcomes Research Institute for an investigation to be conducted within the DD PBRN.

If you are interested in engaging the DD PBRN, please contact the PBRN Shared Resource at pbrn@case.edu or 216-368-4622, or visit their website.

**Events**

**Cordgenics Presentation on ChemoID**
August 18th, Wolstein 3-136, 10am

*Cordgenics* is a dynamic company which applies innovative approaches to develop personalized therapy for cancer. Our goal is to improve the survival rates of cancer patients and to identify novel anticancer drugs for pharmaceutical companies.

- ChemoID technology can assist in optimal chemotherapeutic selection
- Should this technology be adopted by the Case Comprehensive Cancer Center, Cordgenics’ services could be brought to University Hospitals and the Cleveland Clinic, promoting the medical industry and job growth in Ohio
- Cordgenics’ relationship with the Edwards Comprehensive Cancer Center at Huntington Hospital/ Marshall University could be leveraged to be part of the OCTC’s future site expansion.

What Do We Do?

- ChemoID® Drug Sensitivity Testing for Personalized Chemotherapy
- Screening of Drugs for Pharmaceutical companies to target Cancer Stem Cells
- Drug Delivery Technologies

Visit the [Cordgenics website](#) for more information.

**Save the Date: PRCHN Five Year Anniversary!**
Monday, October 6, 2014 | 3:30pm-5:30pm

Please mark your calendar and join the Prevention Research Center for Healthy Neighborhoods on Monday, October 6th, 2014 to celebrate the partnerships and accomplishments of our first 5 years... And the next 5!

**PRCHN Kickoff Reception**
October 6, 2014
3:30-5:30 pm
The Iris S. and Bert L. Wolstein Research Building
Case Western Reserve University
*Valet parking available*

Please RSVP by September 14 to PRCHN2014Launch@gmail.com

**Mark Your Calenders: SOM Institutional Scientific Core Facility Retreat**

The Second Annual SOM Institutional Scientific Core Facility Retreat is scheduled for August 25. Retreat participation is by invitation only and is primarily for Core Facility Directors and Managers, as well as Administrative/Clerical Staff. However, there will be limited additional seating available. If you would like to attend, please follow this link to request an invitation.

**Research Opportunities**

**Pilot Project Grants: American Cancer Society IRG Awards**
Letter of Intent Deadline: Friday, August 15, 2014
Letter of Intent Deadline: Friday, August 15, 2014
Application Deadline: Wednesday, August 27, 2014

- Pilot funding for CANCER-RELATED research in basic, clinical, prevention & control, behavioral, health services and epidemiology
- Up to $30,000 award

Eligibility:
IRG pilot project grants are intended to support independent, self-directed investigators early in their careers (assistant professor or equivalent). Applicants for the pilot project grants should be within 6 years of their first independent research or faculty appointment and eligible to apply for an independent national competitive research grant, but cannot currently hold such a grant.

Recipients of IRG pilot project grants must be, at the time of the application, citizens or noncitizen nationals of the United States or its possessions and territories, or must have been lawfully admitted to the United States for permanent residence at the time of application.

Instructions, frequently asked questions, and applications available online.
Contact: Kristin Waite, Cancer Center Administration, 844-5537, Kristin.waite@case.edu

KL2 Career Development Program 2015
Recruiting Period: July 1 - October 27, 2014

Congratulations to the following, who were selected from a highly competitive pool of applicants, as clinical scholars within the Clinical & Translational Science Collaborative (CTSC) KL2 career development program starting July 1, 2014:

Yong Chen, PhD (Radiology, CWRU)
Glen Taksler, PhD (Medicine, CCF)
Kathy Wright, PhD (Nursing, CWRU Frances Payne Bolton School of Nursing)
Jennifer Yu, MD, PhD (Radiation Oncology, Stem Cell Biology, CCF)

Applications are now being accepted for next year’s awardees, who would begin July 1, 2015.

Qualified candidates are being offered an opportunity to apply to an innovative career development program whose purpose is to train clinician investigators. The CTSC KL2 is designed to train the nation’s future leaders in clinical and translational research, and is part of the NIH Roadmap aimed at “re-engineering the clinical research enterprise.” Each scholar will embark on a 4 year program of intensive training in multidisciplinary team-based, patient-oriented clinical research, combining an innovative curriculum with mentored research experiences.

Qualified candidates:
- Hold an M.D., Ph.D., D.D.S., Pharm.D., Psy.D. or an equivalent degree
- Have demonstrated a keen interest in clinical research
- Need to hold a position in one of the CTSC partner Institutions on or before July 1, 2015
- Are U.S. citizens or have permanent resident status

Applications are encouraged from physicians, nurses, dentists, social and behavioral scientists, engineers, biostatisticians, epidemiologists, bioethicists and other professionals with expertise relevant to clinical research.

Successful applicants will receive a comprehensive package including:
- Salary and benefits commensurate with their qualifications supporting 75% effort
- Research stipend
- Tuition benefits for an innovative didactic program leading to a degree in clinical investigation (half of which will come from a Departmental cost-share)
- Travel funds
- Access to a multidisciplinary pool of highly accomplished mentors who will guide their research projects
- CWRU appointment

The competitive applicant will be at an early career stage, e.g. senior postdoctoral fellow, instructor, or entry level faculty member, and will need to explain through the application how the program will enable a successful career in clinical research.

We are especially seeking qualified applicants from under represented populations.

Please visit our website for more information: [http://casemed.case.edu/ctsc/education/kl2/](http://casemed.case.edu/ctsc/education/kl2/)

For questions or assistance, please contact Beth Spyke, MPA at spykeb@ccf.org or 216-444-2702.

The Clinical and Translational Science Collaborative (CTSC) of Cleveland provides developmental, organizational, financial, and educational support to biomedical researchers as
developmental, organizational, financial, and educational support to biomedical researchers as well as opportunities for community members to participate in meaningful and valuable research.

**CTSC KL2 Upcoming Informational Meetings** (reservations requested):

Cleveland Clinic:  
**September 10, 2014**  
2:00 p.m. - 3:00 p.m.  
Crile Building A8-800

Case Western Reserve University  
**September 11, 2014**  
8:00 a.m. - 9:00 a.m.  
Wolstein Research Building, Room 1403

MetroHealth Medical Center  
**September 17, 2014**  
3:00 p.m. - 4:00 p.m.  
Rammelkamp 219

---

**National Cancer Institute (NCI): Outstanding Investigator Award (OIA)**  
Letter of Intent due September 20th, Application due October 20th by 5:00pm

The NCI is pleased to announce the **Outstanding Investigator Award (OIA)** funding opportunity announcement PAR-14-267. The OIA will support investigators with outstanding records of productivity in cancer research with up to $600,000 in direct costs per year for 7 years to provide funding stability. NCI anticipates making about 50 awards annually.

The OIA will allow funded investigators the freedom to embark on long-term projects of unusual potential in cancer research; the opportunity to take greater risks and be more adventurous in their lines of inquiry; and sufficient time to develop new techniques.

Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding productivity in cancer research as a recipient of NCI grant(s) for at least the past 5 years. The PD/PI will be expected to commit at least 50% of his/her research activities to the OIA; the Institution will be expected to commit at least 20% salary support.

For more information, please see: [PAR-14-267 on the NCI website](#).

---

**Chronic Effects of Neurotrauma Consortium (CENC)**  
Pre-Application Deadline: August 15, 2014

CENC is seeking applications for collaborations and research studies focused on the impact and sequelae of mTBI/CTE on active duty service members and veterans. Studies will address questions and areas complementary to the Consortium’s mission and alignment to specified programmatic needs and funding alignments.

If you are interested in applying, please contact Irene Shaland, Office of Strategic Initiatives, CWRU School of Medicine, at 216.368.4970. Questions regarding this opportunity should be directed to the CENC Peer Review Program Chair, Dr. Steven West at slwest@vcu.edu.

For additional information, visit [the CENC website](#).

---

**AAAS: Marion Milligan Mason Award for Women in the Chemical Sciences**  
Deadline: September 15, 2014

The American Association for the Advancement of Science (AAAS) has announced a new grant opportunity — the **Marion Milligan Mason Award for Women in the Chemical Sciences**.

The objective of the Mason Award is to kick-start the research career of promising future senior investigators in the chemical sciences. The Marion Milligan Mason Fund will provide three grants of $50,000 every other year to women researchers engaged in basic research in the chemical sciences. Awards are for women who are starting their academic research careers. In addition to research funding, the program will provide leadership development and mentoring opportunities.

Applicants must have a "full-time" career-track appointment. More than one applicant from the same institution is encouraged to apply for this award. Applicants must be citizens or permanent residents of the United States, and must complete an application for the Mason Award. Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding productivity in cancer research as a recipient of NCI grant(s) for at least the past 5 years. The PD/PI will be expected to commit at least 50% of his/her research activities to the OIA; the Institution will be expected to commit at least 20% salary support.

For more information, please see: [Mason Award on the AAAS website](#).
Applicants must have a "full-time" career-track appointment. More than one applicant from the same institution can apply for this award, provided that each application is scientifically distinct. Please contact Sandie Moster at sjm127@case.edu if you plan to pursue this opportunity. For additional information, visit the AAAS website.

**Departments of Defense and Veterans Affairs**

**Peer Review Program 2014: Request for Applications**

The Consortium to Alleviate PTSD -- a collaboration involving the STRONG Star Consortium of the University of Texas Health Science Center at San Antonio and VA's National Center for PTSD will attempt to develop the most effective diagnostic, prognostic, novel treatment, and rehabilitative strategies to treat and prevent PTSD.

Submission Deadlines:

- Pre-Proposal Due to CAP Coordinating Center: July 18, 2014
- Invitation for Full Submission for CAP Scientific Review: July 28, 2014
- Full Proposal Submission Due: September 10, 2014
- Pre-Proposal Due to CAP Coordinating Center: August 14, 2014
- Invitation for Full Submission to CAP Scientific Review: August 24, 2014
- Full Proposal Submission Due: December 10, 2014

The RFA focuses on the following areas: Behavioral Health disorders; Mood & Anxiety Disorders; Sexual Dysfunction; Neurologic Disorders; Pain; Cognitive Deficits; Neuroendocrine Deficits.

To see the RFA, please click here: [CAP RRP](#).

**Request for Proposals: Fairbanks Institute: Biological Samples with Longitudinal EHR Data for Research**

The Fairbanks Institute for Healthy Communities (Fairbanks Institute), a non-profit organization, and the Indiana Clinical and Translational Science Institute (CTSI) requests submissions of project applications for research use of bio-specimen with longitudinal electronic medical record data. This application is designed to promote research studies using the Fairbanks Institute’s samples which include coronary artery disease (CAD) and type II diabetes (T2D).

The Fairbanks Institute has created an extensively annotated bio-specimen repository for hypothesis-driven research. These biological samples are linked with longitudinal clinical and disease-specific health records information drawn from the Indiana Network for Patient Care (INPC), a state-wide electronic clinical data repository. The INPC link has enabled the Fairbanks Institute to connect bio-specimens drawn at a point in time or over time with active patient medical record information thereby creating a longitudinal view of the subject’s disease progression, interventions, and outcomes.

All full-time faculty members, regardless of tenure status, having a primary appointment at an Institute with an NIH Clinical and Translation Science Award (CTSA) are eligible to apply.

Proposals deadline is **August 15, 2014 at 4:00 pm**. For more information visit our [website](#).

**Department of Health and Human Services Funding Opportunities**

- NINDS CREATE Devices: Translational and Early Feasibility Studies on the Path to Pre-Market Approval (PMA) or Humanitarian Device Exemption (HDE) (UH2/UH3) Grant: Learn More.